J&J names Thibaut Mongon, current consumer health leader, as CEO of new spin-off company

J&J names Thibaut Mongon, current consumer health leader, as CEO of new spin-off company


Signage is displayed outside of Johnson & Johnson headquarters in New Brunswick, New Jersey, Aug. 1, 2020.

Mark Kauzlarich | Bloomberg | Getty Images

Johnson & Johnson on Wednesday announced that the current head and the chief financial officer of its consumer health portfolio will lead the business when it spins off into a separate publicly traded company in 2023.

Thibaut Mongon, the current leader of the consumer health business, will become CEO of the standalone company, and Paul Ruh will remain in his current role of chief financial officer. Mongon has served as J&J’s consumer health leader since 2019, and Ruh has served as CFO since 2017.

Executive Chair Alex Gorsky said J&J conducted an external executive search, but decided that Mongon and Ruh were best equipped to lead the standalone company.

J&J announced in November that it would sheer off the consumer health business from its faster-growing medical devices and pharmaceutical portfolios.

The consumer health business makes common household products and over-the-counter medicines such as Tylenol, Band-Aid, Listerine, Neutrogena and Aveena skin care, and Johnson’s baby products.

Consumer health sales grew 4.1% to $14.6 billion in 2021, while J&J’s pharmaceutical sales grew 14.3% to $52 billion and medical devices sales grew nearly 18% to $27 billion last year.

In the first quarter of this year, consumer health sales declined 1.5% to $3.59 billion as compared with the same period in 2021, due to supply constraints on ingredients and packaging materials particularly for its skin health and beauty products. However, J&J CFO Joe Wolk said demand was strong for over-the-counter medicine such as Tylenol and Motrin.

The consumer health business faced tens of thousands of lawsuits in recent years that alleged its talc baby powder contained cancer-causing asbestos. J&J created a subsidiary that was placed in bankruptcy to resolve the claims. The company stopped selling the baby powder in the North American market in 2020, but still sells its elsewhere in the world.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:



Source

How twin sister triathletes doubled down on sports success to raise health-startup millions from investors
Health

How twin sister triathletes doubled down on sports success to raise health-startup millions from investors

During their last year of completing work for doctoral degrees in physiology, twin sisters Michal Mor and Merav Mor started to compete in Ironman triathlon races. The demand for peak fitness led them to the realize the importance of understanding personal metabolism, and the lack of data being collected on it through devices accessible to […]

Read More
It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech
Health

It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech

Two graduate students research chemical products in a laboratory in Xiwangzhuang Town, Zaozhuang City, Shandong province of China, on Dec. 26, 2023. Nurphoto | Nurphoto | Getty Images BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development. […]

Read More
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Health

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I’m back in New […]

Read More